Subkutane Rituximab-Formulierung bevorzugt
Crossref DOI link: https://doi.org/10.1007/s15004-015-0790-0
Published Online: 2015-03-27
Published Print: 2015-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
red,
Text and Data Mining valid from 2015-03-01
